Tectonic Therapeutic, Inc. TECX
18.98 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:01 PM EST
18.98 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
18.76 Day range 19.74
15.52 52-week range 39.53
- YTD
- -9.01%
- 1 year
- +8.40%
News
defenseworld.net Tectonic Therapeutic, Inc. (TECX) – What Are Researchers Thinking About This Stock? Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the company, Marketbeat.com reports. One…
benzinga.com UBS Initiates Coverage On Tectonic Therapeutic with Neutral Rating, Announces Price Target of $26 UBS analyst Alice Nettleton initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Neutral rating and announces Price Target of $26.
globenewswire.com Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S. TX2100…
defenseworld.net Tectonic Therapeutic, Inc. (NASDAQ:TECX) Stock Has Average Price Target of $77.25 According to Analysts Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are covering the firm, Marketbeat reports. One…
globenewswire.com Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of…
seekingalpha.com Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case Tectonic Therapeutic offers a validated, severity-enriched trial design for TX45 in CpcPH-HFpEF, with external support from Merck's CADENCE results. Phase 1b TX45 data show promising hemodynamic…
benzinga.com Wells Fargo Maintains Overweight on Tectonic Therapeutic, Lowers Price Target to $93 Wells Fargo analyst Tiago Fauth maintains Tectonic Therapeutic (NASDAQ:TECX) with a Overweight and lowers the price target from $101 to $93.
benzinga.com Tectonic Therapeutic Q2 EPS $(1.18) Beats $(1.37) Estimate Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.18) per share which beat the analyst consensus estimate of $(1.37) by 13.87 percent. This is a 10.28 percent decrease over losses…
globenewswire.com Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) with topline results…
globenewswire.com Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) APEX Phase 2…
benzinga.com Raymond James Upgrades Tectonic Therapeutic to Strong Buy, Raises Price Target to $81 Raymond James analyst Michael Freeman upgrades Tectonic Therapeutic (NASDAQ:TECX) from Outperform to Strong Buy and raises the price target from $76 to $81.- benzinga.com Tectonic Therapeutic Q1 EPS $(1.34) Misses $(1.18) Estimate Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(1.18) by 13.56 percent. This is a 44.09 percent decrease over losses…
globenewswire.com Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and…
globenewswire.com Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of…
seekingalpha.com Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2 Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF, a large underserved market. TX45's engineered Fc-relaxin fusion overcomes prior…
benzinga.com Stifel Initiates Coverage On Tectonic Therapeutic with Buy Rating, Announces Price Target of $75 Stifel analyst James Condulis initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Buy rating and announces Price Target of $75.
defenseworld.net Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $81.50 Consensus Price Target from Analysts Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven brokerages that are covering the company, Marketbeat.com…
defenseworld.net Aberdeen Group plc Acquires 785,648 Shares of Tectonic Therapeutic, Inc. $TECX Aberdeen Group plc boosted its holdings in shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) by 220.6% in the fourth quarter, according to the company in its most recent 13F filing with the…
defenseworld.net Tectonic Therapeutic, Inc. $TECX Shares Sold by Ally Bridge Group NY LLC Ally Bridge Group NY LLC lowered its stake in shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) by 15.3% during the third quarter, according to its most recent disclosure with the Securities and…
defenseworld.net Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of “Moderate Buy” from Brokerages Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the firm, MarketBeat.com reports. One…
seekingalpha.com Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Tectonic Therapeutic Q4 EPS $(1.03) Beats $(1.10) Estimate Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.10) by 6.53 percent. This is a 22.62 percent decrease over losses of…
globenewswire.com Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of…
globenewswire.com Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of…- benzinga.com Here's How Much You Would Have Made Owning Tectonic Therapeutic Stock In The Last 5 Years
globenewswire.com Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Goodyear Tire Posts Downbeat Earnings, Joins BP, ON Semiconductor And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Why Credo Technology Group Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket 
defenseworld.net Tiziana Life Sciences (NASDAQ:TLSA) vs. Tectonic Therapeutic (NASDAQ:TECX) Financial Comparison Tiziana Life Sciences (NASDAQ: TLSA - Get Free Report) and Tectonic Therapeutic (NASDAQ: TECX - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
benzinga.com Truist Securities Maintains Buy on Tectonic Therapeutic, Lowers Price Target to $60 Truist Securities analyst Danielle Brill maintains Tectonic Therapeutic (NASDAQ:TECX) with a Buy and lowers the price target from $64 to $60.- benzinga.com Tectonic Therapeutic Q3 EPS $(1.02) Beats $(1.05) Estimate Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.05) by 2.86 percent. This is a 15 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Oppenheimer Initiates Coverage On Tectonic Therapeutic with Outperform Rating, Announces Price Target of $80 Oppenheimer analyst Leland Gershell initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Outperform rating and announces Price Target of $80.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Canopy Growth, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Truist Securities Initiates Coverage On Tectonic Therapeutic with Buy Rating, Announces Price Target of $64 Truist Securities analyst Danielle Brill initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Buy rating and announces Price Target of $64.
- benzinga.com Raymond James Reinstates Outperform on Tectonic Therapeutic, Announces $76 Price Target Raymond James analyst Michael Freeman reinstates Tectonic Therapeutic (NASDAQ:TECX) with a Outperform and announces $76 price target.
- benzinga.com Reported Saturday, Tectonic Therapeutic Presents Full Phase 1b Results For TX45 in PH-HFpEF Showing Sustained Hemodynamic Improvements And Strong Safety Profile Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved…
benzinga.com Mizuho Maintains Outperform on Tectonic Therapeutic, Raises Price Target to $85 Mizuho analyst Uy Ear maintains Tectonic Therapeutic (NASDAQ:TECX) with a Outperform and raises the price target from $51 to $85.- benzinga.com Tectonic Therapeutic Q1 EPS $(0.93) Beats $(1.22) Estimate Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(0.93) per share which beat the analyst consensus estimate of $(1.22) by 23.77 percent. This is a 91.52 percent increase over losses…